| __timestamp | Gilead Sciences, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 72049000 |
| Thursday, January 1, 2015 | 4006000000 | 110777000 |
| Friday, January 1, 2016 | 4261000000 | 156328000 |
| Sunday, January 1, 2017 | 4371000000 | 175820000 |
| Monday, January 1, 2018 | 4853000000 | 143944000 |
| Tuesday, January 1, 2019 | 4675000000 | 160152000 |
| Wednesday, January 1, 2020 | 4572000000 | 188519000 |
| Friday, January 1, 2021 | 6601000000 | 258234000 |
| Saturday, January 1, 2022 | 5657000000 | 311103000 |
| Sunday, January 1, 2023 | 6498000000 | 384447000 |
| Monday, January 1, 2024 | 28675800000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, Gilead Sciences, Inc. and HUTCHMED (China) Limited stand as intriguing case studies in cost efficiency. From 2014 to 2023, Gilead Sciences consistently demonstrated a robust cost of revenue, peaking at approximately $6.5 billion in 2023. This represents a 72% increase from 2014, showcasing their strategic prowess in managing production costs. In contrast, HUTCHMED, while smaller in scale, exhibited a remarkable growth trajectory, with a 434% increase in cost of revenue over the same period, reaching nearly $384 million in 2023. This growth reflects their expanding footprint in the pharmaceutical industry. The data underscores the contrasting scales and growth strategies of these two companies, offering valuable insights into their operational efficiencies and market strategies.
Cost of Revenue Comparison: AbbVie Inc. vs Gilead Sciences, Inc.
Pfizer Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Gilead Sciences, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Cost Insights: Breaking Down Gilead Sciences, Inc. and Wave Life Sciences Ltd.'s Expenses
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Trends: Pharming Group N.V. vs HUTCHMED (China) Limited
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Travere Therapeutics, Inc.